Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Journal Club ft. NEJM publications • BRCA+ • Breast Cancer, Non-metastatic
Would you recommend adjuvant olaparib in a premenopausal BRCA1+ woman with stage IA pT1bN0 ER/PR+ HER2- breast cancer and a high OncoType score?
The OncotypeDx score was 51 in this scenario.
Answer from: Medical Oncologist at Academic Institution
This is a data-free zone. Although this patient appears to have a high recurrence risk based on her Oncotype RS, she does not seem eligible for adjuvant olaparib based on her clinical-pathological characteristics. The Oncotype RS was not taken into consideration as part of the eligibility criteria i...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In this patient, due to the high Oncotype DX score of 51, there is likely to be a more than 15% absolute benefit of chemotherapy in terms of reducing the risk of distant recurrence based on the TAILORx study, and hence I would definitely offer her adjuvant chemotherapy. In the OlympiA study, as...
Answer from: Medical Oncologist at Community Practice
Agree with the above comments and also important to note that most BRCA patients do have a high Oncotype score.